repartment of Pathology Effective Date: October 20, 2025

TEST CHANGE

Clozapine and Metabolites, Serum or Plasma, Quantitative 2013433, CLOZAP SP

2013433, OLOZAI 31			
Specimen Requirements:			
Patient Preparation:	Timing of specimen collection: Predose(trough) draw?-?—at steady?-—state concentration.		
Collect:	Plain red. Also acceptable: Lavender (K2 or K3EDTA) or pink (K2EDTA).		
Specimen Preparation:	Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP standard transport tube.(Min: 0.5 mL)		
Transport Temperature:	Refrigerated.		
Unacceptable Conditions:	Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution).		
Remarks:			
Stability:	After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 3 months		
Methodology:	Quantitative Liquid Chromatography-Tandem Mass Spectrometry		
Performed:	Sun-Sat		
Reported:	1-5 days		
Note:			
CPT Codes:	80159		
New York DOH Approval Status:	This test is New York DOH approved.		

Interpretive Data:

The Therapeutic ranges are not well established. Clozapine is metabolized to norclozapine and clozapine-N-oxide. Clozapine concentrations between 100 and 700 ng/mL may correlate more with clinical response; however, nonresponsiveness may also occur within this range. For refractory schizophrenia, clozapine concentrations greater than 350 ng/mL are suggested to achieve a therapeutic range is based on serum pre-dose (trough) draw at steady-state concentration_response.

Toxicity: Adverse effects to clozapine therapy may include tachycardia, <u>hematologic disorders</u>, <u>neuroleptic malignant syndrome</u>, <u>elevation of liver enzymes</u>, <u>drowsiness</u>, <u>hypotension</u>, and



A nonprofit enterprise of the University of Utah and its Department of Pathology Effective Date: October 20, 2025

seizures, and tardive dyskinesia. -

Therapeutic and toxic ranges are not well established in children.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA-certified laboratory and is intended for clinical purposes.

Reference Interval:

Test	Therapeutic	Not well	Components	Reference	Interval
Numbe	Range	established			
	Toxic Level	Total			
		Clozapine			
		and			
		Metabolites:			
		Greater than or equal to			
		1500 ng/mL			
		1000 Hg/IIIL	Clazanina N	Thoronout	io and
			Clozapine-N-		
			Oxide, S/P,	toxic rang	<u>es are</u>
			<u>Quant</u>	not well	
				<u>established</u>	
			<u>Norclozapine</u>	. Therapeut	ic and
			S/P, Quant	toxic rang	es are
				not well	
				established	
			Clozapine,		
			S/P, Quant		
				Therapeutic	350-
				Range:	600
					ng/mL
				Toxic:	Greater
					than or
					<u>equal</u>
					<u>to</u>
					1000 ng/mL
					Hg/THL

Deleted Cells	
Inserted Cells	
Inserted Cells	